Try
AGIOS PHARMACEUTICALS, INC.
AGIOUnited States
40 filed reports · 455 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
40 reports · Sep 2015 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 30 | 5,007 | Sep 2015 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 4,255 | Dec 2015 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 366 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 212 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 12, 2026 | 776 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 245 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 155 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 159 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 13, 2025 | 407 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 31, 2024 | 164 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 144 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 2, 2024 | 148 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 15, 2024 | 406 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 171 | Open |
Financial data
455 concepts · 9,262 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial438 concepts · 8,931 facts · Dec 2011 to Jul 2026
- Operating income loss63 · Dec 2013 to Jun 2026
- Allocated share based compensation expense61 · Dec 2013 to Jun 2026
- Comprehensive income net of tax61 · Dec 2013 to Jun 2026
- Net income loss61 · Dec 2013 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax61 · Dec 2013 to Jun 2026
- Research and development expense61 · Dec 2013 to Jun 2026
- Accretion amortization of discounts and premiums investments60 · Dec 2013 to Jun 2026
- Capital expenditures incurred but not yet paid60 · Dec 2013 to Jun 2026
- Increase decrease in accounts payable60 · Dec 2013 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities60 · Dec 2013 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets60 · Dec 2013 to Jun 2026
- Payments to acquire property plant and equipment60 · Dec 2013 to Jun 2026
- Share based compensation60 · Dec 2013 to Jun 2026
- Cash and cash equivalents at carrying value59 · Dec 2013 to Jun 2026
- Revenue59 · Mar 2014 to Jun 2026
- Stockholders equity (US GAAP)59 · Dec 2013 to Jun 2026
- Accounts payable current54 · Dec 2014 to Jun 2026
- Accrued liabilities current54 · Dec 2014 to Jun 2026
- Accrued professional fees current54 · Dec 2014 to Jun 2026
- Accumulated other comprehensive income loss available for sale securities adjustment net of tax54 · Dec 2014 to Jun 2026
- Additional paid in capital common stock54 · Dec 2014 to Jun 2026
- Assets54 · Dec 2014 to Jun 2026
- Assets current54 · Dec 2014 to Jun 2026
- Common stock par or stated value per share54 · Dec 2014 to Jun 2026
Product9 concepts · 227 facts · Dec 2015 to Jun 2026
- Revenue193 · Dec 2016 to Jun 2026
- Licenses9 · Jun 2018 to Dec 2018
- TIBSOVO8 · Sep 2021 to Dec 2022
- Research and development arrangement contract to perform for others compensation earned7 · Mar 2017 to Dec 2018
- Revenue recognition milestone method revenue recognized4 · Dec 2015 to Dec 2017
- License and services revenue2 · Mar 2018
- Revenue (excluding assessed tax)2 · Sep 2019 to Jun 2020
- Milestones achieved1 · Jun 2018
- Royalty income nonoperating1 · Dec 2024
Segment8 concepts · 104 facts · Dec 2022 to Jun 2026
- Revenue18 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Research and development arrangement contract to perform for others compensation earned14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Gain loss on sale of business8 · Dec 2022 to Dec 2025
- Gain on sale of contingent payments8 · Dec 2022 to Dec 2025
Segments
331 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis11 members · 162 facts
- Product54 · Dec 2017 to Jun 2026
- Royalty23 · Dec 2017 to Dec 2024
- Collaboration Revenue Related Party17 · Dec 2017 to Sep 2022
- Collaboration Revenue Other12 · Dec 2017 to Jun 2020
- Commercialization Activity12 · Dec 2017 to Jun 2020
- Research Services12 · Dec 2017 to Jun 2020
- License And Service11 · Dec 2017 to Mar 2020
- Development Activities9 · Dec 2017 to Dec 2019
- TIBSOVO8 · Sep 2021 to Dec 2022
- Committee Participation3 · Dec 2017 to Dec 2019
- Vorasidenib1 · Dec 2024
Statement business segments1 member · 104 facts
- Reportable104 · Dec 2022 to Jun 2026
Product or serviceus-gaap:ProductOrServiceAxis13 members · 65 facts
- Collaboration Revenue Other9 · Dec 2016 to Mar 2019
- Collaboration Revenue Related Party9 · Dec 2016 to Mar 2019
- Product9 · Dec 2016 to Mar 2019
- Royalty9 · Dec 2016 to Mar 2019
- Development Services7 · Mar 2017 to Dec 2018
- Research Services6 · Mar 2018 to Mar 2019
- Committee Participations4 · Mar 2018 to Dec 2018
- IDHIFA4 · Dec 2015 to Dec 2017
- Program Licenses3 · Jun 2018 to Dec 2018
- Development Activities2 · Mar 2018 to Mar 2019
- Other Services1 · Dec 2018
- Product1 · Sep 2019
- Royalty1 · Jun 2020
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.